Top 10 Blue Chip Stocks To Buy Right Now

I will get right to it. After describing the reasons behind its meteoric rise and the discussing why this name was one of my top blue chip top picks for 2017, it comes down to performance. Just this morning Bank of America (NYSE:BAC), as well as other large banks, are out with key earnings reports. This matters for the 2017 call and it matters for the share price which has skyrocketed in the last few months. It’s about the performance. Performance not just on the top and bottom lines but also in several key metrics that I follow closely for all major banks. The bank has come a long way from it facing extinction, and it took we the people to keep it alive. Today Bank of America is one of the largest banks in the United States by assets and yes, it has recovered from the Great Recession. Is it firing on all cylinders like it was pre-recession? No, unfortunately it is not, but it is getting there. Can you stick with the name? We need to examine the company’s most recent earnings and key metrics to make that determination.

Top 10 Blue Chip Stocks To Buy Right Now: MFRI Inc.(MFRI)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, our Under the Radar Moversnewsletter suggestedsmall cap piping systems stock MFRI, Inc (NASDAQ: MFRI) as a short-term long/bullish trade:

Top 10 Blue Chip Stocks To Buy Right Now: Wal-Mart Stores, Inc.(WMT)

Advisors’ Opinion:

  • [By Kumar Abhishek]

    China has a growing middle class and affluent consumers who have strong aspirational demand for western luxury goods. Last year Chinese tourists spent $183 billionon shopping sprees abroad, a good deal of them for buying luxury goods. According to a report on Mintel.com, 58% of the Chinese consumers have boughtforeign goods from local online eCommerce sites. Alibaba has used this trend to build its TmallGlobal. In the just concluded Singles’ day sale, thousands of foreign brands including Walmart (NYSE:WMT) and Apple (NSDQ:AAPL) had participated. A retaliatory tax increase by China on foreign goods will impact the sale of foreign goods. The sale of foreign brands is expected to produce around $2 billion in incremental revenue by next year. A trade war between the US and China willsignificantly impact this revenue source.

  • [By Peter Graham]

    A long term performance chart shows shares of large cap dollar stores Dollar Tree and Dollar General Corp (NYSE: DG) both outperforming Wal-Mart Stores, Inc (NYSE: WMT) and largely given investors roughly the same return:

  • [By Rich Smith]

    Third and finally, Plug’s move closer to Amazon is resulting in customer attrition among the company’s other customers, including Wal-Mart (NYSE:WMT), which may not want to patronize Plug products in the future, knowing that the company is so closely tied to (and may soon be part owned by) Amazon.

Top 10 Blue Chip Stocks To Buy Right Now: Staples, Inc.(SPLS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Staples, Inc. (NASDAQ: SPLS) got a boost, shooting up 7 percent to $9.25 on chatter that the company is targeted for an acquisition. Sycamore Partners, a private equity giant, is reportedly in advanced talks to acquire the office supply retailer, Reuters reported. The deal could value Staples at more than $6 billion, a premium to Staples' valuation of $5.60 billion as of Wednesday's market close.

  • [By Casey Wilson]

    The company was set to merge with its last remaining rival, Staples Inc. (Nasdaq: SPLS), this year, but was denied by a federal judge on May 10 because of antitrust concerns.

  • [By Jeremy Bowman]

    Staples Inc(NASDAQ:SPLS) stock has been on a tear over the last few days amid rumors of a potential buyout.According toThe Wall Street Journal, the company is in talks with private-equity firms to sell itself after regulators blew up its planned merger withOffice Depot(NASDAQ:ODP)last year.

  • [By Ben Levisohn]

    Staples (SPLS) soared to the top of the S&P 500 today on reports that the office-supplies retailer was considering selling itself.

    Agence France-Presse/Getty Images

    Staples gained 9.8% to $9.51 today, while the S&P 500 ticked up 0.1% to 2,360.16.

    CFRA’s Efraim Levy doesn’t see a “natural buyer” for Staples but remain Buy rated anyway:

    Shares are higher on an unconfirmed WSJ report that SPLS is looking at the possible sale of the company. Our fundamentally valued 12-month target of $11, applies a below historical average P/E of 12.1X our FY 18 EPS estimate, given office industry challenges. Our target has 11% upside, plus a 5.5% yield. We don’t see a natural buyer for a large physical store office supply presence, although an activist/private-equity buyer is a possibility. To make an acquisition worthwhile, a buyer would have to be more aggressive in cost cutting and use of cash flow than SPLS’s existing plan.

    Staples’ market capitalization rose to $6.2 billion today from $5.7 billion yesterday. It reported a net loss of $459 million on sales of $18.2 billion in fiscal 2017.

Top 10 Blue Chip Stocks To Buy Right Now: Merck & Company, Inc.(MRK)

Advisors’ Opinion:

  • [By William Romov]

    BioLine has partnerships with major pharmaceutical companies that help bring some of these drugs to launch once they gain some initial success in clinical trials. These partners include Novartis AG (NYSE: NVS) and Merck & Co. Inc. (NYSE: MRK).

  • [By Paul Ausick]

    Merck & Co. Inc. (NYSE: MRK) dropped about 2.9% Monday to post a new 52-week low of $53.63 after closing at $55.02 on Friday. The 52-week high is $66.80. Volume was around 12.7 million, more than 25% above the daily average of about 10 million. The company’s chief competitor in a combo therapy for lung cancer reported a successful phase 3 trial.

  • [By The Ticker Tape]

    LLY recently suffered a setback when approval for the company’s new arthritis drug, co-developed with Incyte Corporation (NASDAQ: INCY), faced delays from the FDA. LLY and INCY disagreed with the FDA’s findings in a company press release and are confident the drug will still be approved in the future. Despite the company’s confidence in the drug, LLY stock dropped about 5% in trading the day the news came out. Even with that drop, it’s still up a little over 11% on the year, outperforming the S&P 500 (SPX) and some of its pharma peers: Merck & Co., Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), and Johnson & Johnson (NYSE: JNJ).

  • [By Matthew Briar]

    Kudos to Merck & Co., Inc. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE) for taking a leap forward in the war against diabetes. The two competitors-turned-partners for one joint venture recently announced the FDA and the European equivalent has accepted an application for permission to sell ertugliflozin and a couple of its derivatives. All the drugs/combos in question are part of the SGLT2 family, which essentially induce the kidneys to filter sugar out of the bloodstream for diabetics whose pancreas isn’t processing that sugar properly.

    It’s an interesting approach, though not one without a potential downside. By forcing the kidneys to do something they weren’t meant to do, eventually, could pose new problems.

    Cell MedX Corp (OTCMKTS:CMXC) is taking an entirely different approach to the treatment of diabetes. Rather than work around a failing pancreas as Merck and Pfizer have, Cell MedX is aiming to fix what’s broken for diabetics. That is, the company aims to restore a body’s cells that properly process sugar by turning them back “on” again using mild electrical currents.

    As much as biologists and the healthcare industry know about the human body, new discoveries are being made all the time regarding our makeup. One of the more recent medical revelations was figuring out animals are not just a collection of chemicals and organic matter, but also electrical impulses. Yes, the human body creates electricity, but more than that, a body can benefit from mild electrical currents, as an electrical charge can put a damaged cell back into its natural, healthy state.

    It may seem like a crazy idea at first, but know the FDA has already given the science of electromedicine the nod of approval as a treatment for chronic pain (called the Cefaly, if you’re curious), and some major companies are wading deeper into electromedicine waters.

    As Scientific American’s Daisy Yuhas noted back in 2013:

Top 10 Blue Chip Stocks To Buy Right Now: Pain Therapeutics(PTIE)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

Top 10 Blue Chip Stocks To Buy Right Now: ZAIS Group Holdings, Inc.(ZAIS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of ZAIS Group Holdings, Inc. (NASDAQ: ZAIS) got a boost, shooting up 48 percent to $3.35. ZAIS Group reported Q4 earnings of $0.29 per share on revenue of $16.73 million.

  • [By Lisa Levin]

    Shares of ZAIS Group Holdings, Inc. (NASDAQ: ZAIS) got a boost, shooting up 42 percent to $3.22. ZAIS Group reported Q4 earnings of $0.29 per share on revenue of $16.73 million.

  • [By Lisa Levin] Related HTGM Mid-Afternoon Market Update: Dow Falls 50 Points; Micron Shares Jump Following Strong Earnings Report Mid-Day Market Update: ZAIS Group Gains Following Q4 Results; Xenon Pharmaceuticals Shares Decline HTG Molecular Diagnostics Completes Initial Technical Feasibility Testing with QIAGEN … (GuruFocus)
    Related Mid-Afternoon Market Update: Dow Falls 50 Points; Micron Shares Jump Following Strong Earnings Report Mid-Day Market Update: ZAIS Group Gains Following Q4 Results; Xenon Pharmaceuticals Shares Decline Zais Group reports Q4 results (Seeking Alpha)
    HTG Molecular Diagnostics Inc (NASDAQ: HTGM) shares climbed 204.1 percent to $11.95 after surging 83.64 percent on Thursday. HTG Molecular Diagnostics reported a Q4 loss of $0.76 per share on revenue of $1.5 million.
    ZAIS Group Holdings, Inc. (NASDAQ: ZAIS) shares surged 52.6 percent to $3.45. ZAIS Group reported Q4 earnings of $0.29 per share on revenue of $16.73 million.
    Global Brokerage Inc (NASDAQ: GLBR) shares jumped 24.3 percent to $2.30.
    Regulus Therapeutics Inc (NASDAQ: RGLS) shares surged 20 percent to $1.50. Regulus Therapeutics’ Chairman bought 500,000 shares at $1.22 per share.
    Rocket Fuel Inc (NASDAQ: FUEL) shares gained 15.6 percent to $5.19.
    Akoustis Technologies Inc (NASDAQ: AKTS) rose 13.3 percent to $10.75 as the company agreed to acquire wafer manufacturing facility for $2.75 million in cash.
    TOP SHIPS Inc (NASDAQ: TOPS) shares gained 12.6 percent to $1.25.
    Inventure Foods Inc (NASDAQ: SNAK) jumped 10.4 percent to $4.46 after the company announced the strategic sale of Fresh Frozen Foods for $23.7 million in cash.
    CymaBay Therapeutics Inc (NASDAQ: CBAY) surged 8.7 percent to $4.14. Cymabay Therapeutics reported a Q4 loss of $0.30 per share.

Top 10 Blue Chip Stocks To Buy Right Now: Regal Entertainment Group(RGC)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Regal Entertainment Group (NYSE: RGC) was already rated as Underperform at Credit Suisse, but the firm said that the chain has weak trends and warned that its forecasts and multiples are just still too high. While raising some estimates, Sheikh lowered his target on Regal Entertainment to $17 from $19 in this call.

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares surged 30.2 percent to $5.01 after dropping 40.86 percent on Tuesday. Marathon Patent Group filed for sale of 1.85 million shares of common stock by selling stockholders.
    Capricor Therapeutics Inc (NASDAQ: CAPR) shares jumped 17.2 percent to $2.25 after the company reported the FDA clearance of Investigational New Drug application for CAP-1002.
    Rite Aid Corporation (NYSE: RAD) gained 13.2 percent to $2.15 following 16.5 percent rally on Tuesday.
    Photronics, Inc. (NASDAQ: PLAB) shares climbed 11.8 percent to $10.45 after the company reported stronger-than-expected earnings for its fourth quarter.
    China Distance Education Hldgs Ltd (ADR) (NYSE: DL) shares surged 11.3 percent to $8.67. China Distance Education reported Q4 profit of $5.9 million on revenue of $41.7 million.
    Cytokinetics, Inc. (NASDAQ: CYTK) shares gained 11 percent to $8.05 after falling 7.05 percent on Tuesday.
    Ooma Inc (NYSE: OOMA) shares surged 8.5 percent to $10.85 as the company posted strong Q3 results.
    Nuance Communications Inc. (NASDAQ: NUAN) climbed 8 percent to $17.12 after the company reported stronger-than-expected results for its fourth quarter on Tuesday.
    American Superconductor Corporation (NASDAQ: AMSC) surged 7.8 percent to $3.59 after the company reported $8 million in D-VAR system orders.
    Thermon Group Holdings Inc (NYSE: THR) rose 6.3 percent to $24.17. William Blair upgraded Thermon Group from Market Perform to Outperform.
    Domino's Pizza, Inc. (NYSE: DPZ) surged 6.1 percent to $182.88. Nomura upgraded Domino's from Neutral to Buy.
    Xencor Inc (NASDAQ: XNCR) rose 5.9 percent to $21.17. Cantor Fitzgerald initiated coverage on Xencor with an Overweight rating.
    Idera Pharmaceuticals Inc (NASDAQ: IDRA) gained 5.1 percent to $2.28 after the company disclosed that it has been granted FDA Fast Track designation for IMO-2125.
    Regal Entertainment Group (NYSE: RGC) gained 5.1 percent to
  • [By Peter Graham]

    In December, UK based Cineworld Group Plc also agreed tobuy larger U.S. peer Regal Entertainment Group (NYSE: RGC) for $3.6 billion in cash in adeal to create the world’s second largest movie theatre operator after AMC Entertainment Holdings. The combined entity is expected to be better able to compete AMC.

Top 10 Blue Chip Stocks To Buy Right Now: Applied Micro Circuits Corporation(AMCC)

Advisors’ Opinion:

  • [By Piyush Arora]

    AMD, along with other server-grade chip manufacturers such as Qualcomm (NSDQ:QCOM), Cavium (NSDQ:CAVM) and AMCC (NSDQ:AMCC), operates in the remaining minuscule 0.8% of the market. So, each of the aforementioned companies operate with a practically non-existent market share, compared to Intels shipments of course. This also means that these firms (AMD, Qualcomm etc.) have plenty of room to grow. This would be subject to good product releases of course, but at least this way, the law of large numbers isnt working against them.

Top 10 Blue Chip Stocks To Buy Right Now: Great Basin Scientific, Inc.(GBSN)

Advisors’ Opinion:

  • [By Paul Ausick]

    Great Basin Scientific Inc. (NASDAQ: GBSN) dropped about 15% on Thursday to post a new 52-week low of $2.90 after closing at $3.42 on Wednesday. The stock’s 52-week high is $45,024.00. Volume was more than 3 times the daily average of around 150,000 shares. The medical diagnostics company had no specific news Thursday. Since mid-March the company has split the stock twice: the first was a 1-for-35 split and the second a 1-for-80 split.

  • [By Lisa Levin]

    Great Basin Scientific Inc (NASDAQ: GBSN) shares dropped 18 percent to $0.92 on Q1 results. Great Basin Scientific posted Q1 net income of $21,503,600, versus a year-ago net loss of $33,652,500.

Top 10 Blue Chip Stocks To Buy Right Now: Safeway Inc.(SWY)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap SUPERVALU now underperforming large cap Kroger Co (NYSE: KR) while shares of large cap Whole Foods Market, Inc (NASDAQ: WFM) and mid cap Safeway Inc (NYSE: SWY) appear to be back to where they started at:

  • [By Peter Graham]

    A long term performance chart shows shares of SUPERVALU underperforming the underperformance ofmid caps Whole Foods Market, Inc (NASDAQ: WFM) and Safeway Inc (NYSE: SWY). while large capKroger Co (NYSE: KR)had outperformed up until the last two years when performance has been more mixed:

Leave a Reply

Your email address will not be published. Required fields are marked *